The IPSS‐M includes mutations in TP53, FLT3, and KMT2A‐PTD as the top predictors of adverse outcomes (PFS, OS, and AML transformation) in patients with MDS [8]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.